article thumbnail

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

The Pharma Data

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with Evusheld.

article thumbnail

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Meeting public expectations of diagnostics is the next big test for the NHS

pharmaphorum

Diagnostics was never a Cinderella sector; Britain has the fifth largest in vitro diagnostics (IVD) market in Europe, not gigantic but significant nevertheless. Before COVID, the UK spent £12 per head on IVD products – around half that of Germany and two thirds of France – according to MedTech Europe.

article thumbnail

A Final LDT Rule in April!? Will FDA be prepared?

FDA Law Blog

However, this prediction is unfounded, because it assumes that there is an existing classification regulation and/or product code for 90% of currently available LDTs. Mullen — With comments due on the proposed LDT rule last week, FDA wasted no time updating the Unified Agenda to indicate that a final rule may be published in April ( here ).

article thumbnail

Vir awarded $1 billion multi-year BARDA influenza contract

pharmaphorum

It has been shown in vitro to cover all major influenza A strains that have arisen since the 1918 ‘Spanish flu’ pandemic and is designed as a universal prophylactic for influenza A. VIR-2482 is an investigational intramuscularly administered influenza A-neutralising mAb.

Antibody 108
article thumbnail

Top 10 Medical Device Companies in 2023 by Revenue Statistics and Trends

XTalks

In Medtronic’s annual report, CEO Geoff Martha attributes their success in this area to their comprehensive suite of products and solutions, which equip clinicians with the tools necessary for optimal atrial fibrillation care. Note: When it comes to companies that report in foreign currencies, the conversion to U.S.

article thumbnail

Healthy.io’s Smartphone-Powered Minuteful Kidney Test Gets FDA Clearance

XTalks

The Minuteful Kidney test kit is delivered to the patient’s home and is made up of all these things needed for in vitro home ACR testing: A urine collection cup. Some factors that can increase the risk of CKD include diabetes, hypertension, cardiovascular disease, smoking, obesity and a family history of kidney disease. Healthy.io Healthy.io

Reagent 98